Alector LLC

Michael Kurnellas

Arnon Rosenthal

Tina Schwabe

Robert Pejchal

Anthony B Cooper

Robert Pejchat

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-Sortilin antibodies and methods of use thereof

Anti-sortilin antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.

Methods of use of anti-Sortilin antibodies for treating a disease, disorder, or injury

Methods of increasing progranulin levels using anti-Sortilin antibodies

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Isolated nucleic acids encoding anti-sortilin antibodies

Growing community of inventors

San Francisco, CA, United States of America

Michael Kurnellas